SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Job Trends
Bonus Episode: Q2 2025 Job Market Update
In this bonus episode, BioSpace’s Vice President of Marketing ⁠Chantal Dresner⁠ and Careers Editor ⁠Angela Gabriel⁠ take a look at Q2 job market performance, layoffs and wider employment trends and policies impacting the biopharma workforce.
July 15, 2025
 · 
1 min read
 · 
Angela Gabriel
Entrance to the U.S. Department of Health and Human Services in Washington, DC
Layoffs
HHS Begins Formally Laying Off Employees
Thousands of employees across HHS were terminated Monday evening after the U.S. Supreme Court ruled last week that the Trump administration could move forward with its sweeping reorganization of the agency.
July 15, 2025
 · 
2 min read
 · 
Tristan Manalac
Wood block with healthcare medical icon on blue background. Health care insurance concept
Infectious disease
Gilead, GSK/ViiV, Merck Present New HIV PrEP Frontiers at IAS25
HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the heels of the landmark Yeztugo approval.
July 15, 2025
 · 
4 min read
 · 
Tristan Manalac
Policy
FDA Commissioner Marty Makary Proposes Lowering Industry User Fees
According to Makary, reducing user fees—which make up just under half of the FDA’s budget—could make it easier for smaller companies, individual investors and academics to participate in the process.
July 15, 2025
 · 
2 min read
 · 
Tristan Manalac
Contemporary art collage. Conceptual design with young woman, motivated employee running forward to reach goal, professional success. Concept of business, career development, achievement
Obesity
Hengrui’s Dual GLP-1/GIP Elicits 17.7% Weight Loss in Phase III
The molecule, developed in collaboration with Massachusetts-based Kailera Therapeutics, is headed for a new drug application in China and global clinical trials.
July 15, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Acadia CEO Catherine Owen Adams,
Rare diseases
Acadia Debuts New Team, Pipeline With ‘Biotech Powerhouse’ Ambitions
More than thirty years since its 1993 founding, Catherine Owen Adams and Elizabeth Thompson—the R&D combo that has led Acadia since last year—are managing two products on the market and a pipeline estimated to be worth an additional $12 billion in sales.
July 15, 2025
 · 
5 min read
 · 
Heather McKenzie
World Management Team in office silhouette 3d rendering
Drug Development
The Gap Between the Administration’s Pro-Innovation Words and Policy
Despite the FDA commissioner’s promises of partnership and collaboration, personnel changes and continued federal cuts create uncertainty for an industry already struggling with nearly half a decade of investment scarcity.

July 14, 2025
 · 
6 min read
 · 
Lori Ellis
3d rendering medical heart in yellow background
Cardiovascular disease
AstraZeneca’s Baxdrostat Pushes Blood Pressure Lower in Phase III Trial
The drug came to AstraZeneca through its acquisition of CinCor Pharma in 2023, with the hopes of beefing up its cardiovascular and kidney disease pipelines.
July 14, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Pictured: Takeda sign at its office in Massachusetts
Neuroscience
Takeda Establishes Lead in Narcolepsy Race With Back-to-Back Phase III Wins
Takeda’s oveporexton improved wakefulness, attention and other key narcolepsy endpoints “with a high degree of statistical significance,” according to Jefferies analysts.
July 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS